WO2006090750A8 - 抗IgSF4抗体及びその利用 - Google Patents

抗IgSF4抗体及びその利用

Info

Publication number
WO2006090750A8
WO2006090750A8 PCT/JP2006/303195 JP2006303195W WO2006090750A8 WO 2006090750 A8 WO2006090750 A8 WO 2006090750A8 JP 2006303195 W JP2006303195 W JP 2006303195W WO 2006090750 A8 WO2006090750 A8 WO 2006090750A8
Authority
WO
WIPO (PCT)
Prior art keywords
igsf4
antibody
treating
molecule
utilization
Prior art date
Application number
PCT/JP2006/303195
Other languages
English (en)
French (fr)
Other versions
WO2006090750A1 (ja
Inventor
Yoshikazu Kurosawa
Yasushi Akahori
Atsushi Sugioka
Nobuhiro Hayashi
Akihiko Takasaki
Kazuhiro Suzuki
Miwa Morita
Gene Kurosawa
Yoshitaka Iba
Mariko Sumitomo
Susumu Tsutsumi
Keiko Ogawa
Kazuki Matsuda
Chiho Muramatsu
Nobuhiro Takahashi
Sari Fujiyama
Masachika Azuma
Yoshinori Ukai
Kazuhiro Morishita
Original Assignee
Inst Antibodies Co Ltd
Yoshikazu Kurosawa
Yasushi Akahori
Atsushi Sugioka
Nobuhiro Hayashi
Akihiko Takasaki
Kazuhiro Suzuki
Miwa Morita
Gene Kurosawa
Yoshitaka Iba
Mariko Sumitomo
Susumu Tsutsumi
Keiko Ogawa
Kazuki Matsuda
Chiho Muramatsu
Nobuhiro Takahashi
Sari Fujiyama
Masachika Azuma
Yoshinori Ukai
Kazuhiro Morishita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Antibodies Co Ltd, Yoshikazu Kurosawa, Yasushi Akahori, Atsushi Sugioka, Nobuhiro Hayashi, Akihiko Takasaki, Kazuhiro Suzuki, Miwa Morita, Gene Kurosawa, Yoshitaka Iba, Mariko Sumitomo, Susumu Tsutsumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Nobuhiro Takahashi, Sari Fujiyama, Masachika Azuma, Yoshinori Ukai, Kazuhiro Morishita filed Critical Inst Antibodies Co Ltd
Priority to EP06714335A priority Critical patent/EP1860119B1/en
Priority to US11/885,245 priority patent/US8048992B2/en
Priority to JP2007504753A priority patent/JP4942644B2/ja
Priority to AU2006216291A priority patent/AU2006216291B2/en
Publication of WO2006090750A1 publication Critical patent/WO2006090750A1/ja
Publication of WO2006090750A8 publication Critical patent/WO2006090750A8/ja
Priority to US13/238,096 priority patent/US20120046451A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

　癌治療や癌診断の標的となる分子を明らかにし、当該分子の医療分野又は研究分野での利用を図る。肝癌細胞特異的に発現する分子としてIgSF4が同定され、当該分子に抗体を作用させることでADCC活性が発揮された。この知見に基づいて本発明の一局面では癌治療等に有効な手段としての抗IgSF4抗体が提供される。
PCT/JP2006/303195 2005-02-27 2006-02-22 抗IgSF4抗体及びその利用 WO2006090750A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP06714335A EP1860119B1 (en) 2005-02-28 2006-02-22 ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME
US11/885,245 US8048992B2 (en) 2005-02-28 2006-02-22 Anti-IgSF4 antibody and utilization of the same
JP2007504753A JP4942644B2 (ja) 2005-02-28 2006-02-22 抗ＩｇＳＦ４抗体及びその利用
AU2006216291A AU2006216291B2 (en) 2005-02-27 2006-02-22 Anti-IgSF4 antibody and utilization of the same
US13/238,096 US20120046451A1 (en) 2005-02-28 2011-09-21 ANTI-lgSF4 ANTIBODY AND UTILIZATION OF THE SAME

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005-054624 2005-02-27
JP2005054624 2005-02-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/885,245 A-371-Of-International US8048992B2 (en) 2005-02-28 2006-02-22 Anti-IgSF4 antibody and utilization of the same
US13/238,096 Division US20120046451A1 (en) 2005-02-28 2011-09-21 ANTI-lgSF4 ANTIBODY AND UTILIZATION OF THE SAME

Publications (2)

Publication Number Publication Date
WO2006090750A1 WO2006090750A1 (ja) 2006-08-31
WO2006090750A8 true WO2006090750A8 (ja) 2008-01-10

Family

ID=36927388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/303195 WO2006090750A1 (ja) 2005-02-27 2006-02-22 抗IgSF4抗体及びその利用

Country Status (6)

Country Link
US (2) US8048992B2 (ja)
EP (1) EP1860119B1 (ja)
JP (1) JP4942644B2 (ja)
CN (1) CN101137671A (ja)
AU (1) AU2006216291B2 (ja)
WO (1) WO2006090750A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202568B2 (en) 2013-08-12 2019-02-12 Invivosciences Inc. Automated cell culture system and method

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5131946B2 (ja) * 2005-09-13 2013-01-30 国立大学法人 東京大学 がんの診断、処置および／または予防、および／または浸潤・転移の抑制のための方法、システムおよび組成物ならびに関連するスクリーニング方法
WO2008007648A1 (fr) 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
ES2625259T3 (es) * 2006-08-29 2017-07-19 Oxford Biotherapeutics Ltd Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
GB2455634A (en) * 2007-12-20 2009-06-24 Ucb Pharma Sa Treatment of cancer
EP2282769A4 (en) * 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
JP5723769B2 (ja) * 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP2321422A4 (en) * 2008-07-08 2013-06-19 Abbvie Inc PROSTAGLANDINE E2 VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
PT2403878T (pt) * 2009-03-05 2017-09-01 Squibb & Sons Llc Anticorpos completamente humanos específicos a cadm1
US20110008766A1 (en) * 2009-05-01 2011-01-13 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011047262A2 (en) * 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
JP5980202B2 (ja) * 2011-05-09 2016-08-31 株式会社ペルセウスプロテオミクス トランスフェリン受容体を特異的に認識できる抗体
JP2013040912A (ja) * 2011-08-18 2013-02-28 Miyazakiken Sangyo Shien Zaidan 成人ｔ細胞白血病診断器具
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
JP5939855B2 (ja) * 2012-03-23 2016-06-22 国立大学法人 宮崎大学 トランスフェリン受容体抗体
AT512783B1 (de) * 2012-05-22 2013-11-15 Bosch Gmbh Robert Verfahren zum Rollieren einer zylindrischen Bauteilfläche
BR112015009961B1 (pt) 2012-11-01 2020-10-20 Abbvie Inc. proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
PT2918603T (pt) * 2012-11-08 2018-10-30 Univ Miyazaki Anticorpo capaz de reconhecer especificamente o receptor da transferrina
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
JP6440968B2 (ja) * 2013-05-28 2018-12-19 国立大学法人 宮崎大学 ＩｇＳＦ４／ＴＳＬＣ１／ＣＡＤＭ１を特異的に認識できる抗体
WO2015034052A1 (ja) 2013-09-05 2015-03-12 国立大学法人 宮崎大学 ヒトインテグリンａ６ｂ４と特異的に反応する抗体
CN104020030B (zh) * 2014-06-09 2017-03-01 北京农学院 一种扫描电镜用的昆虫样品的制备方法
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EA201991514A1 (ru) * 2016-12-21 2019-12-30 Сефалон, Инк. Антитела, которые специфически связываются с ил-15, и их применение
WO2021201571A1 (ko) * 2020-03-31 2021-10-07 웰마커바이오 주식회사 Igsf1 에 대한 항체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 및 이를 이용한 암 치료 방법
KR20220105139A (ko) * 2021-01-19 2022-07-26 광주과학기술원 Igsf4의 막 관통 도메인을 발현하는 t 세포 및 이의 이용
US20240262906A1 (en) * 2021-08-20 2024-08-08 Wellmarker Bio Co., Ltd. Anti-igsf1 antibody and use thereof
CN114213544B (zh) * 2021-12-21 2023-05-23 江苏帆博生物制品有限公司 异嗜性抗体阻断剂hbr-7及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3709230A1 (de) 1987-03-20 1988-10-06 Desitin Arzneimittel Gmbh Neues calciumsalz der valproinsaeure
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1264885A4 (en) 2000-02-22 2007-02-21 Med & Biological Lab Co Ltd ANTIBODY LIBRARY
AU2001262750A1 (en) 2000-06-14 2001-12-24 Medical And Biological Laboratories Co., Ltd. Method of constructing scfv antibody fused with fluorescent protein
DE60136212D1 (de) * 2000-08-15 2008-11-27 Univ Johns Hopkins Med Diagnose und behandlung von tumor-suppressor assoziierten krankheiten
JP4121123B2 (ja) 2003-05-20 2008-07-23 富士通株式会社 移動体通信方法及びシステム
WO2005012530A2 (en) * 2003-07-25 2005-02-10 Amgen Inc. Antagonists and agonists of ldcam and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202568B2 (en) 2013-08-12 2019-02-12 Invivosciences Inc. Automated cell culture system and method

Also Published As

Publication number Publication date
AU2006216291A1 (en) 2006-08-31
AU2006216291B2 (en) 2011-01-27
CN101137671A (zh) 2008-03-05
US20120046451A1 (en) 2012-02-23
JPWO2006090750A1 (ja) 2008-07-24
US8048992B2 (en) 2011-11-01
JP4942644B2 (ja) 2012-05-30
EP1860119B1 (en) 2011-08-03
WO2006090750A1 (ja) 2006-08-31
US20090053243A1 (en) 2009-02-26
EP1860119A4 (en) 2009-04-15
EP1860119A1 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
WO2006090750A8 (ja) 抗IgSF4抗体及びその利用
WO2008089397A3 (en) Adrb2 cancer markers
WO2007047408A3 (en) Promac signature application
WO2007093657A3 (es) Método para el diagnóstico molecular de cáncer de próstata y kit para implementar el método
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
WO2006135684A3 (en) Methods and kits for sense rna synthesis
WO2009012140A3 (en) Drug selection for lung cancer therapy using antibody-based arrays
WO2007149481A3 (en) Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
WO2010081001A3 (en) Recurrent gene fusions in cancer
WO2005005601A3 (en) Compositions and methods for treating and diagnosing cancer
WO2006097743A3 (en) Method for actvating natural killer cells by tumor cell preparation in vitro
WO2011034906A3 (en) Recurrent gene fusions in prostate cancer
WO2006101387A3 (en) Method for interfering with blood coagulation by modulating cross-beta structures fibril formation
WO2004050707A3 (de) Tumorspezifische erkennungsmoleküle
WO2007050348A3 (en) Potassium channel inhibitors
WO2007067984A3 (en) Neutralizing antibodies against primate psgl-1 and uses therefor
EP2631248A3 (en) Treatment of tumors using specific anti-L1 antibody
WO2007038264A3 (en) Gapr-1 methods
WO2011029008A3 (en) Synbodies to akt1
WO2007149105A3 (en) Fluorescein based sensors for tracking nitric oxide in live cells
WO2008118733A3 (en) Methods of treating cancer by administering human il-18 combinations
EP2708894A3 (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
WO2007072018A3 (en) Redox mediators
WO2009137139A3 (en) Methods of determining antibiotic resistance

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680005983.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007504753

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006216291

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006216291

Country of ref document: AU

Date of ref document: 20060222

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006216291

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006714335

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006714335

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11885245

Country of ref document: US